Table 1.

Number (%) of CLL cases and their matched controls by certain socioeconomic and clinical characteristics

Case (N = 1,385)Control (N = 6,841)
Male825 (59.6%)4,100 (59.9%)
Age group
 40–54151 (10.9%)737 (10.8%)
 55–64328 (23.7%)1,621 (23.7%)
 65–74403 (29.1%)2,009 (29.4%)
 75+503 (36.3%)2,474 (36.2%)
 In top 60% of household income distribution800 (57.8%)3,804 (55.6%)
 Rural residence521 (37.6%)2,472 (36.1%)
Comorbidities
 Diabetes229 (16.5%)1,231 (18.0%)
 Chronic cardiovascular disease (excluding hypertension)579 (41.8%)2,719 (39.7%)
 Ischemic heart diseases261 (18.8%)1,284 (18.8%)
 Stroke33 (2.4%)200 (2.9%)
Ever-use of statins
 Any statin371 (26.8%)1,918 (28.0%)
 Any statin 2–5 years prior to the index date341 (24.6%)1,739 (25.4%)
 Any statin 6–10 years prior to the index date219 (15.8%)1,139 (16.6%)
 Any statin 11+ years prior to the index date93 (6.7%)462 (6.8%)
 Hydrophilic statins131 (9.5%)591 (8.6%)
 High-potency lipophilic statins290 (20.9%)1,500 (21.9%)
 Low-potency lipophilic statins40 (2.9%)287 (4.2%)
 Pravastatin67 (4.8%)299 (4.4%)
 Rosuvastatin73 (5.3%)330 (4.8%)
 Simvastatin113 (8.2%)572 (8.4%)
 Atorvastatin218 (15.7%)1,113 (16.3%)
 Fluvastatin15 (1.1%)111 (1.6%)
 Lovastatin28 (2.0%)199 (2.9%)
Ever-use of other prescription drugs
 Non-statin lipid-lowering drugs101 (7.3%)464 (6.8%)
 Metformin123 (8.9%)681 (10.0%)
 Insulin32 (2.3%)169 (2.5%)
 Other oral hypoglycemic drugs113 (8.2%)604 (8.8%)
 Aspirin249 (18.0%)1,392 (20.3%)
 Non-aspirin NSAID844 (60.9%)4,340 (63.4%)
 Any NSAID911 (65.8%)4,721 (69.0%)
No. of physician visits in the 5-year period before index date
 0–19261 (18.8%)1,495 (21.9%)
 20–39388 (28.0%)2,014 (29.4%)
 40–64380 (27.4%)1,656 (24.2%)
 65+356 (25.7%)1,676 (24.5%)